ADC Therapeutics
ADCT
37 hedge funds and large institutions have $57.7M invested in ADC Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.
63% more capital invested
Capital invested by funds: $35.4M → $57.7M (+$22.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 41 → 37 (-4)
9.92% less ownership
Funds ownership: 48.93% → 39.01% (-9.9%)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$1.06M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$987K |
| 3 |
Morgan Stanley
New York
|
+$830K |
| 4 |
Goldman Sachs
New York
|
+$375K |
| 5 |
Jane Street
New York
|
+$93.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.96M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$1.48M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$964K |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$958K |
| 5 |
BlackRock
New York
|
-$475K |
ADCT Hedge Fund Activity: Q4 2023 in Review
37 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2023, worth a combined $57.7M — up 63% from $35.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADCT and 7 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Redmile Group, adding an estimated $1.06M. The largest seller was Sio Capital Management, exiting entirely with an estimated $2.96M sold.
- 37 institutional investors held ADC Therapeutics (ADCT) as of Q4 2023, down from 41 in Q3 2023.
- Funds reported $57.7M of ADC Therapeutics stock for Q4 2023, up 63% quarter-over-quarter.
- 7 funds opened new ADC Therapeutics positions in Q4 2023 and 11 closed out, a net change of -4 holders.
- The largest ADC Therapeutics buyer in Q4 2023 was Redmile Group, an estimated $1.06M added.
- The largest ADC Therapeutics seller in Q4 2023 was Sio Capital Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q4 2023.